Two Major Healthcare Acquisitions in China: YingTai Medical to Acquire 23.18% Stake in Valgen for $108M, Dongxing Medical to Buy 90% of Wuhan Yijiabao for RMB 770M

　　【Pharmaceutical Network Industry DynamicsSince May 2026, global healthcare M&A activities have significantly increased. Against the backdrop of frequent billion-dollar integrations by leading companies and highly focused sectors, Chinese enterprises have also completed multiple M&A deals exceeding hundreds of millions to strengthen their pipelines.
 

Recently, INT Medical announced that it plans to spend approximately US$108 million to acquire 23.18% of Valgen Holding Corporation, which holds 100% equity of Delta Medical.
 

It is reported that INT Medical focuses on the research, development, production, and sales of interventional treatment technologies and products for atrioventricular valve diseases. Four of its self-developed products have been included in the special review process for innovative medical devices by the National Medical Products Administration (NMPA). Among them, the DragonFly™ Transcatheter Mitral Valve Clip System is the first domestically produced transcatheter mitral valve product approved by the NMPA in China. This acquisition is expected to further expand INT Medical's product pipeline in the field of structural heart disease and enhance the group's overall competitiveness and long-term development potential in the cardiovascular intervention field.
 

On May 12, Dongxing Medical announced that the company plans to acquire 90% of the equity in Yijiabao (Wuhan Medplus Biomaterials Co., Ltd.) held by Bao Shijun and Hubei Tianhui Technology Development Co., Ltd. through a cash payment method for a transaction price of 770 million yuan. After the completion of this transaction, Yijiabao will become a holding subsidiary of the company.
 

The target company mainly engages in the research, development, production, and sales of orthopedic and biomedical materials. This acquisition will enrich Jiangsu Canopus Wisdom Medical Technology Co., Ltd.'s product portfolio, enabling a full-process extension from intraoperative instruments to intraoperative implants and postoperative repair, and building an integrated solution capability of devices plus biomaterials in the broader surgical field.
 

In fact, since the beginning of this year, there have been several large-scale mergers and acquisitions in China's medical field focusing on frontier technology positioning, industrial chain integration, and state-owned capital deployment. For instance, in February, Eyebright Medical officially announced its cross-industry entry into the sports medicine sector. According to the announcement, Eyebright Medical plans to acquire 68.31% of Delta Medical’s equity for a consideration of 6.83 billion yuan through a combination of acquisition loans and its own funds.
 

Delta Medical is a technology-based enterprise focusing on the sports health industry, with a full-chain product line covering preoperative prevention, surgical treatment, and postoperative rehabilitation. Its products include 13 types of centralized procurement selected products such as titanium alloy suture anchors and meniscus repair suturing consumables.
 

On February 9, Huajian Medical disclosed that it had received the Shenzhen Stock Exchange's share transfer confirmation, marking the official regulatory compliance confirmation of the B-Soft Co., Ltd. agreement transfer between Ge Hang and Hangzhou Better Wisdom Investment. According to the previous agreement, Huajian Medical will acquire 6.23% of B-Soft Co., Ltd.'s equity for 500 million yuan through its platform.
 

It is reported that Huajian Medical's takeover of B-Soft Co., Ltd. essentially aims to fill in the scarce pieces of scenarios and data in the AI medical ecosystem. Huajian Medical plans to systematically integrate its algorithmic capabilities (A) into B-Soft’s intellectual property and scenario foundation (K). Combined with BsoftGPT, B-Soft’s large medical model, and hospital clinical data, this integration will create a more precise disease early warning and auxiliary diagnosis system.
 

　　……
 

Overall, mergers and acquisitions (M&A) in China's medical field have shifted from pure scale expansion to the acquisition of technology platforms (siRNA, ADC), integration within high-value consumables sectors, and the establishment of digital closed-loop systems. In the future, through these M&A activities, Chinese companies are expected to accelerate their deep integration into the global medical innovation ecosystem, becoming a significant and indispensable force in industry development.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.